Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Hexarelin

Examorelin, HEX

Quick Stats
Studies 233
Trials 61
Score 3
1999 pubmed

Identification and characterization of a new growth hormone-releasing peptide receptor in the heart.

Bodart. V V; Bouchard. J F JF; McNicoll. N N; Escher. E E; Carrière. P P; Ghigo. E E; Sejlitz. T T; Sirois. M G MG; Lamontagne. D D; Ong. H H

Key Findings

  • Hexarelin raises coronary perfusion pressure (vasoconstriction) in a dose‑dependent way in isolated rat hearts
  • The vasoconstriction is partially blocked by L‑type Ca²⁺ channel and PKC inhibitors, indicating those pathways are involved
  • A distinct 84 kDa hexarelin receptor in heart tissue was identified, with high affinity, and is not displaced by other GH secretagogues

Practical Outcomes

  • Hexarelin may affect heart blood‑vessel tone, so users should monitor cardiovascular health and be cautious with dosing. The findings suggest potential heart‑protective benefits but also a risk of vasoconstriction, highlighting the need for more research before incorporating hexarelin into longevity or performance protocols.

Summary

Hexarelin, a peptide that boosts growth hormone, also tightens the blood vessels in the heart of rats by acting on a newly found heart‑specific receptor. This effect uses calcium channels and protein kinase C, not the usual prostaglandin pathways, and other similar GH‑releasing drugs don’t cause it. While it may help protect the heart after a lack of blood flow, the vasoconstriction could be a safety concern for people using hexarelin for performance or longevity.

Abstract

Hexarelin, a synthetic hexapeptide of the growth hormone-releasing peptide (GHRP) family with strong growth hormone (GH)-releasing activity, features protecting activity against postischemic ventricular dysfunction in hearts from GH-deficient and senescent rats. To document whether hexarelin action is mediated through specific cardiac receptors, perfusion of Langendorff rat hearts with hexarelin and binding studies were carried out. In the Langendorff rat heart system, hexarelin induced a dose-dependent increase in coronary perfusion pressure. Nifedipine, chelerythrine, and bisindolylmaleimide partially inhibited the vasoconstriction induced by hexarelin, suggesting that this effect was mediated at least in part by L-type Ca(2+) channels and protein kinase C. In contrast, diclofenac and 1-(7-carboxyheptyl)imidazole were without effect, suggesting that prostaglandins and thromboxanes were not involved in the coronary vasoconstriction induced by hexarelin. To characterize the hexarelin binding sites in the rat heart, [(125)I]Tyr-Bpa-Ala-hexarelin was used as photoactivatable radioligand in saturation and competitive binding studies. We specifically labeled a hexarelin receptor with an M(r) of 84 000 in rat cardiac membranes. Saturation binding curves revealed a single class of binding sites with a K(d) of 14.5 nmol/L and a density of 91 fmol/mg of protein. Competition binding studies gave an IC(50) of 2.9 micromol/L for hexarelin; MK-0677 and EP51389, both potent GH secretagogues, did not displace the binding of the photoactivatable derivative from rat cardiac membranes. Interestingly, both compounds were devoid of any vasoconstrictive activity. These results suggest the existence of a new class of hexarelin receptor in the heart, whose role in the regulation of the coronary vascular tone is yet to be determined.

Study Information

Provider

pubmed

Year

1999

Date

1999-10-29T00:00:00.000Z

DOI

10.1161/01.res.85.9.796